Tiziana Life Sciences Stock (NASDAQ:TLSA)
Previous Close
$0.78
52W Range
$0.41 - $1.74
50D Avg
$0.95
200D Avg
$0.86
Market Cap
$75.41M
Avg Vol (3M)
$301.27K
Beta
0.18
Div Yield
-
TLSA Company Profile
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
TLSA Performance
Peer Comparison
Ticker | Company |
---|---|
SPRC | SciSparc Ltd. |
CRVS | Corvus Pharmaceuticals, Inc. |
BHVN | Biohaven Pharmaceutical Holding Company Ltd. |
INBX | Inhibrx Biosciences, Inc. |
ADAP | Adaptimmune Therapeutics plc |
QNRX | Quoin Pharmaceuticals, Ltd. |
APTO | Aptose Biosciences Inc. |
AFMD | Affimed N.V. |
BNOX | Bionomics Limited |
LPTX | Leap Therapeutics, Inc. |
IMNM | Immunome, Inc. |
CMND | Clearmind Medicine Inc. |